Inter-patient radiosensitivity explained 85–97% of modeled TCP steepness, while uncertainty in delivered dose exceeded uncertainty in local-control estimates.
Repeated end-expiratory breath-hold CBCT achieved boundary sharpness statistically equivalent to daily CT in 10 pancreatic SBRT patients.
Alternative shielding materials reduced modeled linac vault area by 17–34% while remaining below the NCRP controlled-area dose goal.
The unshielded SunSILICON detector required only modest corrections in small fields, while the shielded version became unreliable below approximately 2 cm.
Model-predicted 16–18° lens rotations reduced residual refractive cylinder by 1.7–2.4 D across four representative clinical scenarios.
Inter-centre material variability supports shared QA datasets and standardized acceptance criteria for clinical radiotherapy 3D printing.
Five-year progression-free and overall survival were 55.4% and 64.6%, with metastatic status and histologic response remaining major prognostic factors.
SGRT triggered verification in 15% of head and neck fractions, but almost half of alerts were not confirmed on X-ray imaging.
Dose to neck skin, subcutaneous tissue, and sternocleidomastoid muscle predicted fibrosis burden in nonsurgical head and neck cancer survivors.
Range of motion improved by nearly 29° after revision arthroplasty preceded by 8 Gy, with parallel improvements in pain and function.
Carbon-ion schedules produced similar tumour outcomes, but sacral insufficiency fractures occurred in 47% versus 24% with 4 Gy(RBE) fractions.
Empty-bladder SBRT was feasible in 85% of screened patients, with grade 2 or higher urinary toxicity of 28.1%.
Three-year outcomes numerically favored 50.4 Gy over 60 Gy, while multivariable analysis found no significant survival advantage from either dose.
Grade 2 dermatitis fell from 38.6% to 25.3% with 16-fraction whole-breast radiotherapy plus simultaneous integrated boost.
4DCT ventilation predicted postoperative FEV1, FVC, and DLCO with concordance coefficients of 0.88–0.91 in the LIME trial.